Latest news articles

Added 5 years ago Drug news

FDA approves updated Surfaxin (Discovery Labs) for RDS

The FDA has agreed to Discovery Lab's updated product specifications for Surfaxin (lucinactant) Intratracheal Suspension which was approved in 2012...

Added 7 years ago Drug news

Surfaxin (Discovery Labs) is FDA approved for Respiratory Distress Syndrome

The FDA has approved Surfaxin (lucinactant) from Discovery Laboratories for the prevention of Respiratory Distress Syndrome (RDS), a breathing disorder...

Added 7 years ago Drug news

Surfaxin is re-filed at FDA for Respiratory Distress Syndrome

The FDA has accepted the re-application for the humanised surfactant Surfaxin (lucinactant) from Discovery Laboratories as a preventive therapy for...

Search all news articles for Respiratory distress syndrome of newborn
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more